HEART STENT REVENUES REDUCE ANGIOTECH EARNINGS

Lower revenues from its partner in the heart stent business dropped Angiotech Pharmaceuticals Inc. profits in the first quarter to $7.5 million (U.S.) from a year-ago $18.8 million, the company reported Tuesday.
The Toronto Star